Table 2 Discontinuations and reasons for discontinuations*
IFX | GLM | GLM-IV | |
|---|---|---|---|
Total discontinuations (n/N, %) | 659/890, 74.0% | 280/530, 65.6% | 71/157, 45.2% |
Exposure (Total, Mean pt. yrs) | 2714, 3.0 | 1077, 2.0 | 257, 1.6 |
Reason for discontinuation (n, %a) | |||
Patient withdrew consent | 58, 8.8% | 25, 8.9% | 4, 5.6% |
Adverse event | 116, 17.6% | 33, 11.8% | 10, 14.1% |
Lost to follow-up | 25, 3.8% | 28, 10.0% | 7, 9.9% |
Financial reasons | 14, 2.1% | 4, 1.4% | 0, 0.0% |
Complete response | 10, 1.5% | 4, 1.4% | 0, 0.0% |
Disease progression | 75, 11.4% | 14, 5.0% | 2, 2.8% |
Lack of response | 45, 6.8% | 67, 23.9% | 22, 31.0% |
Loss of response | 65, 9.9% | 46, 16.4% | 6, 8.5% |
Unusual lack of efficacy | 0, 0% | 1, 0.4% | 0, 0% |
Geographic issues | 24, 3.6% | 3, 1.1% | 2, 2.8% |
Patient switched to another therapy | 32, 4.9% | 15, 5.4% | 9, 12.7% |
Did not meet entry criteria | 1, 0.2% | 0, 0.0% | 0, 0.0% |
Other | 191, 29.0% | 40, 14.3% | 8, 11.3% |
Missing | 3, 0.5% | 0, 0% | 1, 1.4% |